{"ticker": {"uuid": "6a4cd0c8-4d16-49ec-9f00-c3984014c762", "symbol": "ADMA", "name": "ADMA Biologics Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "ADMA Deadline Alert: Levi & Korsinsky Reminds ADMA BIOLOGICS, INC. (ADMA) Investors of Securities Class Action Deadline on August 10, 2026", "summary": "Levi & Korsinsky, LLP reminds investors of ADMA Biologics, Inc. (ADMA) about a securities class action lawsuit deadline on August 10, 2026. The lawsuit alleges ADMA used \"channel stuffing\" to falsely inflate ASCENIV revenues, turning a reported 20% growth into an estimated 3% dec", "url": "https://www.globenewswire.com/news-release/2026/06/22/3315388/3080/en/adma-deadline-alert-levi-korsinsky-reminds-adma-biologics-inc-adma-investors-of-securities-class-action-deadline-on-august-10-2026.html", "source_name": "GlobeNewswire", "published_at": "2026-06-22T13:39:20", "published_display": "22 Jun 2026 13:39", "sentiment": "negative", "sentiment_pct": 15, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADMA Alert: ADMA Biologics Investors may have been Misled", "summary": "A securities fraud class action lawsuit has been filed against ADMA Biologics, Inc. (NASDAQ:ADMA) and its executives. This action follows a significant stock drop attributed to allegations of \"channel stuffing\" by Culper Research, leading to a reported 20% revenue growth in 2025 ", "url": "https://www.globenewswire.com/news-release/2026/06/22/3315140/0/en/adma-alert-adma-biologics-investors-may-have-been-misled-about-alleged-channel-stuffing-contact-bfa-law-about-the-pending-securities-fraud-class-action.html", "source_name": "GlobeNewswire", "published_at": "2026-06-22T10:39:20", "published_display": "22 Jun 2026 10:39", "sentiment": "negative", "sentiment_pct": 15, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "INVESTOR DEADLINE ALERT: ADMA Biologics, Inc. (ADMA) Investors With Substantial Losses Have Opportunity to Lead Class Action Lawsuit", "summary": "", "url": "https://news.google.com/rss/articles/CBMi_gFBVV95cUxOSmlKWmdvNE04a3psTk9ocDljTFdqdGlLTWJ6MWhCRExFRjJWbGM0V1F6aGVYY2hrYW9MMG5NcWlBdHpDSm02SDBkc0ZZYXNlQjFDQjNGTm13UlNvNFo1TW1XWmQwLW5pcXJzeHNFUVpqRGR0UHBEZkxGaGZLX2NRRDZxMWVfcFdVVVVkeGxRZjFNcTVHZW5Nb3lzMGdyMUdBeDR5YzJIem9ZbFFad1R1alI5WEtZTkpjdUFQTWNpdEVBVm9ILUt1SEhPZWFaY3Jvb1FyRkFYajQyQ3JhQ0lLdmJFampibnBPYWJoRWtVNkJLLUtqNzZzU2o4cDBRZw?oc=5", "source_name": "NewMediaWire", "published_at": "2026-06-21T21:40:18+00:00", "published_display": "21 Jun 2026 21:40", "sentiment": "negative", "sentiment_pct": 18, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADMA ALERT: Securities Fraud Class Action Launched Against ADMA Biologics, Inc. \u2013 August 10, 2026 Deadline", "summary": "Levi & Korsinsky, LLP has filed a securities class action lawsuit against ADMA Biologics, Inc. on behalf of investors who purchased securities between August 9, 2024, and March 25, 2026. The lawsuit alleges that ADMA Biologics engaged in an undisclosed related party transaction, ", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/adma-alert-securities-fraud-class-action-launched-against-adma-b-1180017", "source_name": "ACCESS Newswire", "published_at": "2026-06-21T22:39:20", "published_display": "21 Jun 2026 22:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Class Action Lawsuit Filed: ADMA Biologics, Inc. (ADMA) \u2013 Join by August 10, 2026 \u2013 Contact Levi & Korsinsky", "summary": "Levi & Korsinsky, LLP has filed a securities class action lawsuit against ADMA Biologics, Inc. on behalf of investors who purchased securities between August 9, 2024, and March 25, 2026. The lawsuit alleges that ADMA Biologics made false statements, concealed a related party tran", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/class-action-lawsuit-filed-adma-biologics-inc.-adma-%E2%80%93-join-by-au-1179926", "source_name": "ACCESS Newswire", "published_at": "2026-06-21T20:10:15", "published_display": "21 Jun 2026 20:10", "sentiment": "negative", "sentiment_pct": 9, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Reminder for ADMA Biologics Securities Class Action", "summary": "The article serves as a reminder for investors who purchased ADMA Biologics securities between August 9, 2024, and March 25, 2026, to apply as lead plaintiff in a class action lawsuit by August 10, 2026. The lawsuit alleges that ADMA Biologics made false statements, including und", "url": "https://intellectia.ai/news/stock/reminder-for-adma-biologics-securities-class-action", "source_name": "Intellectia AI", "published_at": "2026-06-21T13:09:41", "published_display": "21 Jun 2026 13:09", "sentiment": "negative", "sentiment_pct": 27, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADMA Investors Have Opportunity to Lead ADMA Biologics, Inc. Securities Fraud Lawsuit Filed by The Rosen Law Firm", "summary": "The Rosen Law Firm has filed a securities class action lawsuit against ADMA Biologics, Inc., alleging securities fraud for misleading statements about undisclosed related-party transactions, channel stuffing, and inadequate internal controls. Investors who purchased ADMA securiti", "url": "https://www.prnewswire.com/news-releases/adma-investors-have-opportunity-to-lead-adma-biologics-inc-securities-fraud-lawsuit-filed-by-the-rosen-law-firm-302805651.html", "source_name": "PR Newswire", "published_at": "2026-06-21T12:09:40", "published_display": "21 Jun 2026 12:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADMA Biologics (ADMA) Hit With Federal Securities Lawsuit Over Revenue Inflation Allegations", "summary": "ADMA Biologics (NASDAQ:ADMA) is facing a federal securities lawsuit alleging revenue inflation through channel stuffing and concealed distribution relationships, following a short-seller report. This legal challenge comes despite a recent \"Outperform\" rating from Raymond James, w", "url": "https://finance.yahoo.com/markets/stocks/articles/adma-biologics-adma-hit-federal-203437698.html", "source_name": "Market source", "published_at": "2026-06-20T16:34:00", "published_display": "20 Jun 2026 16:34", "sentiment": "negative", "sentiment_pct": 18, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADMA Biologics, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline", "summary": "Kahn Swick & Foti, LLC (KSF) has issued a notice regarding a class action securities lawsuit against ADMA Biologics, Inc. Investors who purchased ADMA securities between August 9, 2024, and March 25, 2026, and suffered losses, have until August 10, 2026, to apply for lead plainti", "url": "https://www.theglobeandmail.com/investing/markets/stocks/ADMA-Q/pressreleases/2560049/adma-biologics-inc-notice-of-august-10-2026-application-deadline-for-class-action-lawsuit-contact-lewis-kahn-esq-at-kahn-swick-foti-llc-before-application-deadline/", "source_name": "The Globe and Mail", "published_at": "2026-06-20T03:40:20", "published_display": "20 Jun 2026 03:40", "sentiment": "negative", "sentiment_pct": 14, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADMA Biologics, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit", "summary": "Kahn Swick & Foti, LLC (KSF) has issued a notice for a class action lawsuit against ADMA Biologics, Inc., informing investors of an August 10, 2026, application deadline to serve as lead plaintiff. The lawsuit alleges that ADMA Biologics and its executives failed to disclose mate", "url": "https://www.streetinsider.com/Newsfile/ADMA+Biologics%2C+Inc.+Notice+of+August+10%2C+2026+Application+Deadline+for+Class+Action+Lawsuit+-+Contact+Lewis+Kahn%2C+Esq.+at+Kahn+Swick+%26+Foti%2C+LLC%2C+Before+Application+Deadline/26668447.html", "source_name": "StreetInsider", "published_at": "2026-06-19T19:38:52", "published_display": "19 Jun 2026 19:38", "sentiment": "negative", "sentiment_pct": 13, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ROSEN, THE FIRST FILING FIRM, Encourages ADMA Biologics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm \u2013 ADMA", "summary": "The Rosen Law Firm is encouraging investors of ADMA Biologics, Inc. (NASDAQ: ADMA) who purchased securities between August 9, 2024, and March 25, 2026, to secure legal counsel before the August 10, 2026 lead plaintiff deadline in a securities class action. The lawsuit alleges tha", "url": "https://www.globenewswire.com/news-release/2026/06/19/3314871/0/en/ROSEN-THE-FIRST-FILING-FIRM-Encourages-ADMA-Biologics-Inc-Investors-to-Secure-Counsel-Before-Important-Deadline-in-Securities-Class-Action-First-Filed-by-the-Firm-ADMA.html", "source_name": "GlobeNewswire", "published_at": "2026-06-19T17:38:52", "published_display": "19 Jun 2026 17:38", "sentiment": "negative", "sentiment_pct": 30, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Adma Biologics Inc (ADMA) Affects Rotational Strategy Timing", "summary": "This article analyzes Adma Biologics Inc (ADMA) using AI models to provide insights for rotational strategy timing. It identifies strong near and mid-term sentiment but a weak long-term outlook, with a notable 159.0:1 risk-reward setup. The report details specific institutional t", "url": "https://news.stocktradersdaily.com/news_release/22/How_Adma_Biologics_Inc_ADMA_Affects_Rotational_Strategy_Timing_061926025601_1781895361.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-19T14:56:00", "published_display": "19 Jun 2026 14:56", "sentiment": "positive", "sentiment_pct": 70, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADMA Shareholder Alert: August 10, 2026 Lead Plaintiff Deadline in ADMA Biologics, Inc. ...", "summary": "The Gross Law Firm has issued a shareholder alert for ADMA Biologics, Inc. (NASDAQ: ADMA) due to alleged materially false and/or misleading statements made during the period of August 7, 2026, to March 25, 2026. Shareholders who purchased ADMA shares during this time are encourag", "url": "https://www.caledonianrecord.com/adma-shareholder-alert-august-10-2026-lead-plaintiff-deadline-in-adma-biologics-inc/article_1366e2c3-815d-523e-a7f2-a3e967a99669.html", "source_name": "Caledonian Record", "published_at": "2026-06-19T14:16:00", "published_display": "19 Jun 2026 14:16", "sentiment": "negative", "sentiment_pct": 13, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADMA INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP", "summary": "Robbins Geller Rudman & Dowd LLP has announced a class action lawsuit against ADMA Biologics, Inc. (NASDAQ: ADMA) for alleged violations of the Securities Exchange Act of 1934. Investors who purchased ADMA securities between August 9, 2024, and March 25, 2026, and suffered substa", "url": "https://www.globenewswire.com/news-release/2026/06/19/3314877/0/en/adma-investor-notice-robbins-geller-rudman-dowd-llp-announces-that-adma-biologics-inc-investors-with-substantial-losses-have-opportunity-to-lead-class-action-lawsuit.html", "source_name": "GlobeNewswire", "published_at": "2026-06-19T14:15:00", "published_display": "19 Jun 2026 14:15", "sentiment": "negative", "sentiment_pct": 19, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADMA Investors Have Opportunity to Lead ADMA Biologics, Inc. Securities Fraud Lawsuit with the Schall Law Firm", "summary": "The Schall Law Firm is reminding investors of a class action lawsuit filed against ADMA Biologics, Inc. for alleged securities fraud. The lawsuit claims that ADMA made false and misleading statements, failed to disclose a related party transaction, used channel stuffing, and lack", "url": "https://www.globenewswire.com/news-release/2026/06/19/3314763/0/en/adma-investors-have-opportunity-to-lead-adma-biologics-inc-securities-fraud-lawsuit-with-the-schall-law-firm.html", "source_name": "GlobeNewswire", "published_at": "2026-06-19T14:10:00", "published_display": "19 Jun 2026 14:10", "sentiment": "negative", "sentiment_pct": 19, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Investor Rights Alert: ADMA Biologics (ADMA) Faces Securities Fraud Class Action after Channel Stuffing Allegations Cause 29% Stock Drop \u2013 Investors Notified to Contact BFA Law", "summary": "A class action lawsuit has been filed against ADMA Biologics, Inc. (NASDAQ:ADMA) and its executives for securities fraud. This action follows a significant stock drop attributed to allegations by Culper Research of channel stuffing to inflate reported revenue growth for 2025. Inv", "url": "https://www.globenewswire.com/news-release/2026/06/19/3314680/0/en/Investor-Rights-Alert-ADMA-Biologics-ADMA-Faces-Securities-Fraud-Class-Action-after-Channel-Stuffing-Allegations-Cause-29-Stock-Drop-Investors-Notified-to-Contact-BFA-Law.html", "source_name": "GlobeNewswire", "published_at": "2026-06-19T10:10:00", "published_display": "19 Jun 2026 10:10", "sentiment": "negative", "sentiment_pct": 10, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "5 Stocks Under $20 That Will Explode", "summary": "The article discusses ADMA Biologics, Inc. (NASDAQ: ADMA) as one of five stocks under $20 with high upside potential, despite facing a federal securities lawsuit alleging channel stuffing and misleading statements. Raymond James issued an \"Outperform\" rating and a $21 price targe", "url": "https://www.insidermonkey.com/blog/5-stocks-under-20-that-will-explode-1784343/5/", "source_name": "Insider Monkey", "published_at": "2026-06-19T00:12:29", "published_display": "19 Jun 2026 00:12", "sentiment": "negative", "sentiment_pct": 39, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Investors Alert: Class Action Lawsuits Against ADMA, ERAS, NNOX", "summary": "Class action lawsuits have been filed against ADMA Biologics, Erasca, Inc., and Nano-X Imaging Ltd. for allegedly making false or misleading statements that led to investor losses. Holzer & Holzer, LLC is representing shareholders in these cases, with deadlines for lead plaintiff", "url": "https://intellectia.ai/news/stock/investors-alert-class-action-lawsuits-against-adma-eras-nnox", "source_name": "Intellectia AI", "published_at": "2026-06-18T21:12:29", "published_display": "18 Jun 2026 21:12", "sentiment": "negative", "sentiment_pct": 17, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADMA Biologics, Inc. (ADMA) Class Action Lawsuit: Investors Face August 10, 2026, Deadline", "summary": "Kessler Topaz Meltzer & Check, LLP has announced a securities fraud class action lawsuit against ADMA Biologics, Inc. (ADMA). The lawsuit alleges material misstatements and omissions regarding the company's revenues and internal controls, including undisclosed related-party trans", "url": "https://www.prnewswire.com/news-releases/adma-biologics-inc-adma-class-action-lawsuit-investors-face-august-10-2026-deadline-302802887.html", "source_name": "PR Newswire", "published_at": "2026-06-18T18:12:29", "published_display": "18 Jun 2026 18:12", "sentiment": "negative", "sentiment_pct": 19, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Deadline Alert: ADMA Biologics, Inc. (ADMA) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAJBVV95cUxPbnZzNklOeGVrd0ludmJLTHpVaVFXcVhaLUh4bWRqTmJDYWlXSnBBVllqWE5NeG1HWEhGNEdPc0ZYN2xkcXc2V2xMWlV3Ym9qLW5lSTVSaklzSWttNndvRmpYa29hLXlyczBZcHZuSjV5ckZsTXJNN2xnQlNaU3g2YXphMkRlWUh1bFgxZDhmUEs5VmExNDV3Q3JfeFY0eTYzX09IU2xqcFotSExPd01EeGV1N0RHSHJITmgxMWN4ODV4ZjdlaVRiRjhNa3dQYlkxZGVTVFp0WGVWakF1aUtsU0FzSGlZVDVHYkgtSGxRNGMwUV9ncGdOejhVOFBpc2JYVmlEN1NlN3ZQcS1GaEd6aWJaaFJPcjhOR0d1LTlSOHlKVVhwUThRWFBMQk9UVFZCdjJUWUxlanJuT3VYT3otVWhvRjQ?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-06-18T16:00:00+00:00", "published_display": "18 Jun 2026 16:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Deadline Alert: ADMA Biologics, Inc. (ADMA) Shareholders", "summary": "Glancy Prongay Wolke & Rotter LLP has issued a deadline alert for investors who lost money in ADMA Biologics, Inc. (ADMA) securities, urging them to contact the firm regarding a securities fraud lawsuit. The class action alleges that ADMA made materially false and misleading stat", "url": "https://www.globenewswire.com/news-release/2026/06/18/3314387/0/en/deadline-alert-adma-biologics-inc-adma-shareholders-who-lost-money-urged-to-contact-glancy-prongay-wolke-rotter-llp-about-securities-fraud-lawsuit.html", "source_name": "GlobeNewswire", "published_at": "2026-06-18T16:12:29", "published_display": "18 Jun 2026 16:12", "sentiment": "negative", "sentiment_pct": 13, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADMA Biologics Shareholder Alert: ClaimsFiler Reminds", "summary": "ClaimsFiler is alerting investors with significant losses in ADMA Biologics, Inc. (NasdaqGM: ADMA) to a lead plaintiff deadline of August 10, 2026, in a securities class action lawsuit. The lawsuit alleges that ADMA and its executives made false and misleading statements, includi", "url": "https://www.globenewswire.com/news-release/2026/06/18/3314344/35454/en/adma-biologics-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-100-000-of-lead-plaintiff-deadline-in-class-action-lawsuit-against-adma-biologics-inc-adma.html", "source_name": "GlobeNewswire", "published_at": "2026-06-18T15:12:29", "published_display": "18 Jun 2026 15:12", "sentiment": "negative", "sentiment_pct": 10, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADMA Shareholder Alert: ADMA BIOLOGICS, INC. Securities Class Action Lawsuit - Investors Should Contact SueWallSt", "summary": "SueWallSt has issued a shareholder alert regarding a securities class action lawsuit against ADMA Biologics, Inc. (NASDAQ: ADMA). The lawsuit alleges the company made misleading statements about its revenue recognition, internal controls, and related party transactions, specifica", "url": "https://www.prnewswire.com/news-releases/adma-shareholder-alert-adma-biologics-inc-securities-class-action-lawsuit---investors-should-contact-suewallst-302803661.html", "source_name": "PR Newswire", "published_at": "2026-06-18T14:12:29", "published_display": "18 Jun 2026 14:12", "sentiment": "negative", "sentiment_pct": 20, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ADMA Biologics, Inc. of Class Action Lawsuit and Upcoming Deadlines - ADMA", "summary": "Pomerantz LLP has filed a class action lawsuit against ADMA Biologics, Inc. (NASDAQ: ADMA) on behalf of investors who incurred losses. The lawsuit alleges securities fraud following a Culper Research report claiming \"channel stuffing\" and an undisclosed related party distributor ", "url": "https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-reminds-investors-with-losses-on-their-investment-in-adma-biologics-inc-of-class-action-lawsuit-and-upcoming-deadlines--adma-302802832.html", "source_name": "PR Newswire", "published_at": "2026-06-18T14:00:28", "published_display": "18 Jun 2026 14:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Grabar Law Office Investigates ADMA Biologics, Inc. (ADMA) on Behalf of Long-Term Shareholders", "summary": "Grabar Law Office is investigating ADMA Biologics, Inc. (ADMA) regarding potential breaches of fiduciary duties by its officers and directors. The investigation focuses on allegations of inadequate internal controls, inflated revenue through channel-stuffing, undisclosed related-", "url": "https://www.newsfilecorp.com/release/302043/Grabar-Law-Office-Investigates-ADMA-Biologics-Inc.-ADMA-on-Behalf-of-LongTerm-Shareholders", "source_name": "TMX Newsfile", "published_at": "2026-06-18T12:40:28", "published_display": "18 Jun 2026 12:40", "sentiment": "negative", "sentiment_pct": 19, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adma Biologics (ADMA) Dips More Than Broader Market: What You Should Know", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxPbk5relpGSkt4ZlNCTkROaHR2aDMzZGliMmVMTlBEbXNtcFZvOUxKWlVYdXN3RU1fVUF4SlFuYTR0Q3RRNmJGQ2xkV0MxT0tYNU1TUnhPWk1GQmdDQjl5a3BrTi1fajJrNjJDcTIyUExfcmdHekV4TGFqcUlSdWotaEhPYnM0WWI4VGo1TnN4eUY0eTFDWTdReVhR?oc=5", "source_name": "Market source", "published_at": "2026-06-17T21:50:02+00:00", "published_display": "17 Jun 2026 21:50", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADMA LAWSUIT ALERT: Bragar Eagel & Squire, P.C. Announces", "summary": "Bragar Eagel & Squire, P.C. announced a class action lawsuit against ADMA Biologics, Inc. (NASDAQ:ADMA) for alleged false and misleading statements, including an undisclosed related party transaction and channel stuffing. The lawsuit covers investors who purchased ADMA securities", "url": "https://www.globenewswire.com/news-release/2026/06/17/3313864/0/en/adma-lawsuit-alert-bragar-eagel-squire-p-c-announces-that-a-class-action-lawsuit-has-been-filed-against-adma-biologics-inc-and-encourages-investors-to-contact-the-firm.html", "source_name": "GlobeNewswire", "published_at": "2026-06-17T22:39:30", "published_display": "17 Jun 2026 22:39", "sentiment": "negative", "sentiment_pct": 13, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Class Action Alert: Levi & Korsinsky Reminds ADMA Biologics, Inc. (ADMA) Investors of August 10, 2026 Deadline", "summary": "Levi & Korsinsky, LLP has filed a securities class action lawsuit against ADMA Biologics, Inc. (NASDAQ:ADMA) on behalf of investors who suffered losses due to alleged securities fraud between August 9, 2024, and March 25, 2026. The lawsuit claims ADMA Biologics engaged in an undi", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/class-action-alert-levi-and-korsinsky-reminds-adma-biologics-inc-1178565", "source_name": "ACCESS Newswire", "published_at": "2026-06-17T21:39:30", "published_display": "17 Jun 2026 21:39", "sentiment": "negative", "sentiment_pct": 19, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADMA DEADLINE: Levi & Korsinsky Reminds ADMA BIOLOGICS, INC. Investors of Upcoming Securities Class Action Deadline", "summary": "Levi & Korsinsky, LLP reminds investors of ADMA Biologics, Inc. (NASDAQ: ADMA) about a looming securities class action deadline of August 10, 2026. The lawsuit alleges that ADMA falsely certified effective internal controls while engaging in a channel stuffing scheme and conceali", "url": "https://www.prnewswire.com/news-releases/adma-deadline-levi--korsinsky-reminds-adma-biologics-inc-investors-of-upcoming-securities-class-action-deadline-302802430.html", "source_name": "PR Newswire", "published_at": "2026-06-17T14:39:30", "published_display": "17 Jun 2026 14:39", "sentiment": "negative", "sentiment_pct": 13, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Portnoy Law Firm Announces Class Action on Behalf of ADMA Biologics, Inc. Investors", "summary": "The Portnoy Law Firm has announced a class action lawsuit against ADMA Biologics, Inc. on behalf of investors who purchased securities between August 9, 2024, and March 25, 2026. The lawsuit alleges that ADMA Biologics and its executives failed to disclose material information, i", "url": "https://www.globenewswire.com/news-release/2026/06/17/3313582/0/en/Portnoy-Law-Firm-Announces-Class-Action-on-Behalf-of-ADMA-Biologics-Inc-Investors.html", "source_name": "GlobeNewswire", "published_at": "2026-06-17T14:06:06", "published_display": "17 Jun 2026 14:06", "sentiment": "negative", "sentiment_pct": 14, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "INVESTOR NOTICE: ADMA Biologics, Inc. (ADMA) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0gJBVV95cUxQV0FqX2QtVE1ESHMzQ0ZRcFVldkV1NjEtejVJbXZwTFR3WkNFdUdudEhtUHQxQ245ZFFVZkU5ME5aUi12bkF1dUlEZUFtN19xQlY4YkFvaGFGdFM3aHBKRE94SHA4WDZ1SUE4OWJVLUlkaV9fUk9OZ3hUaWdnZEgwQWQwN3VIYTY0alczbkNHWFhkRUpVN21rTU42bkVIbVlCMWI3dW8yYWRJa1E1Y2J1TUUwcGxjWDVuVUhSbXE0NGxFSWVqeDUtM0Z6UXZxRWxMYWktaUZtOGNlaHhwdUI0MVZLOXJEMmdvdGFzbU03c19VVk9KVnJuNTJLRm1YR0c3UUs0MEJhb05UQnlFaG1mMUVYblVVcUJkU3F4WHFPbWZvYVhoNmRrSEVDRWZKU3Q4M19lTEE4S0dBT0FLWVdjXzVVdXlkNkxzaWhOeEpYZHVzQQ?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-06-16T21:20:00+00:00", "published_display": "16 Jun 2026 21:20", "sentiment": "negative", "sentiment_pct": 18, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADMA Biologics (ADMA) Stock Valuation After Revenue Inflation Lawsuits And Governance Concerns", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-14T11:25:16+00:00", "published_display": "14 Jun 2026 11:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADMA Biologics Faces Class Action Lawsuit for Securities Fraud", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxNYnl0STRMbFBGZHZRSGlsRzFBdXR4UTVHYjBmSFBFUWtZOTd1R1dRN1Rmc2E1YnZtazQwSlBDaVNHbWpDbzRlWk9xNlAzV3RHcGxCZUFIRnJha0dhelVHSW5jX05ObWtrMXJnZWw4SjJSU3hTdVc0c1FQUGhRS2NTMURpUy1JTG96Z3VEOEFRRS1LQ1NsdDQ2dHJEbmY?oc=5", "source_name": "Intellectia AI", "published_at": "2026-06-12T11:57:07+00:00", "published_display": "12 Jun 2026 11:57", "sentiment": "negative", "sentiment_pct": 34, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adma Biologics (ADMA) Stock Dips While Market Gains: Key Facts", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPMmYzT05rY0sxSzNkSDNoaHBiZDFvZ1hUVE4wVDhiVWNXWVJnWUpNTC16Y2p4cVpZS0JwdzNZdHQtaUFzR1JTdDN4Ri13bDBfT1JQWWVZMk1NTVh3M3poZjNVX0xFNGFFWnZ6M1ZadVEzaXJkY3NPUHRISGFWWFBIREUzdkotUWZzLXpPMFRvMFNzSHQyVnhjQlJxWQ?oc=5", "source_name": "Market source", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why ADMA Biologics (ADMA) Is Up 9.3% After Securities Fraud Class Actions Over ASCENIV Sales Practices", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4gFBVV95cUxQcVZOZlVXNkhhWmVTTzVLa09yQ1g0R2RPdEE1RmN0cHhjZUZzenA3Z0Y2UzhUY21JS180QlZaRlNXd1VkOW50SWJPaVJNVnIxY085b1FWNGR4SUVXbndVM3JpSTFrRjhaZ0hyMG9uTEVMdzFPWnlra01KRlYxa0p2SG03bElIUmdzcjJfQUItRHk1YXJNa2w3NWNUNzRKR3MyLVVWT3cxVVJFWjNLWjVzSWhWZGI0YWM3blA1eTBOOVFvM3RLOFhuZENIYXBwUXlTakNGR1dfbUVubjNydnFhZVFR?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Investor Notice: Robbins LLP Informs Investors of the ADMA Biologics, Inc. Class Action Lawsuit", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5AFBVV95cUxOelZJN0wyeXFUOVBvZkozVnZzVUNxU2dvelotZXBkd2dGNU02X0lSaXBOamZZV1NZVGhHNTIzckxZWm43S1A5SGZTYUdfQnMyei1iWHk0dlVxVXFpeDdMZXBlbDVLbS1BVkR0b094LXdLUGU5TEJwakNuRUZKTHg4WEFqYU5aTGNiMHR0R3dPTVFQdUk4VE0zMjhWUjg4UjRsVFhweXdmejRHeGlnS0hsaFl5R0lkem9kaDQzX1lBOTdaYXczVzFVTWJ6Z3ZzZE5ZN2RveEFOVkdsVjc2b3Q0SllaQXc?oc=5", "source_name": "Business Wire", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adma Biologics (ADMA) Down 5.8% Since Last Earnings Report: Can It Rebound?", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/adma-biologics-adma-down-5-153018267.html", "source_name": "Zacks", "published_at": "2026-06-05T15:30:18+00:00", "published_display": "05 Jun 2026 15:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADMA Biologics (ADMA) Valuation After 2026 Guidance Reset And BIVIGAM Headwinds", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/adma-biologics-adma-valuation-2026-200843695.html", "source_name": "Simply Wall St.", "published_at": "2026-06-01T20:08:43+00:00", "published_display": "01 Jun 2026 20:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADMA Biologics (ADMA) Receives FDA Label Expansion for ASCENIV", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/adma-biologics-adma-receives-fda-113719750.html", "source_name": "Insider Monkey", "published_at": "2026-06-01T11:37:19+00:00", "published_display": "01 Jun 2026 11:37", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is ADMA Biologics, Inc. (ADMA) Among the Best Russell 2000 Stocks to Invest In According to Hedge Funds?", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/adma-biologics-inc-adma-among-080341722.html", "source_name": "Insider Monkey", "published_at": "2026-06-01T08:03:41+00:00", "published_display": "01 Jun 2026 08:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADMA Biologics Inc (ADMA) Stock Analysis: Exploring a 109.90% Potential Upside Amid Robust Revenue Growth", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxQY1VPcVJQZjdPY0Iyc2ZjWUg3TUpMQjZwSGloM1QzYUcxZTFYejVoa1liYjNzMjNtMGZySExFSXRYRFBZdVo1YUNQdFhfaFp2RERsN3dFMWhTb1Z5RVJfd1V4aXItWUM3UjYzdXl0WEs0OWJYZmJDUTRHcHctMnlmclk2VlJnU3NMRG5NVlRiZ25CNGUycEtUYUsyVkRIU3IyZUFlS2p2a3k2bzZRelBwTVNIdmtjX1FFcXJJQlZBeEUxVEh3bWo2QWFEN3lNM3l2OVNYR0hFa0tPRnMyYVJQSE1MZ3VJMlU?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is it Time to Exit ADMA Biologics Stock After a 22% Monthly Plunge?", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxNQS16dklZVlVqakZoSVJ5LXBfQkk4TmI3cGFFTjlHR0hEZnJkbWlUeWNkRXZQRjNmb1RYdTRfMnlDT0p6QUQ5c1JUSGx1ak05dUpnQnRHYUtfcFJuczRrWUpwc0JqSmNWMzlMX0F5S0hvWm9EZFpycG9EMDFKdkthRTJabThWNkt2cnh6blNxM0MzOHA5WHlyZEZCRQ?oc=5", "source_name": "Market source", "published_at": "2026-05-19T07:00:00+00:00", "published_display": "19 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxQcjZqdzdBcURDdWxCZUtoU1dTaHYtVUFRdlo1a3ZGZGY3a1dBX2x2UVE3Y1hoX1duLXhGU2p0UXU2eTctNng5eFJ5c1M0bHBNQ0VmZTFZanhYU21yTVo0UTQtVENveVV1aWdpc3luUlgza3AyUEI2OGx4aEhXc0pBTHpWUThSYXI1S3RTS21lQ21vWjd6MGY4ZDRwVWlEakc3SmFKN09aM0Rlb2pFT3BNNW1GTExnSElFb2NqR3JhX0J3MlptQy1mMk9IOTZtdS1HU25fLU9aOU9XZi1PRDlkZVI2cnhackHSAewBQVVfeXFMTlc2N3pIUkxDd1NtTlVRMEdac1JNSDF3cUNidkZrTElQREZaUTZjZmFHdUVWYW8wcDg1LThGbnlPb0VQUFI4ZXdjSXR6Ym5DREM1X2lyQUtYTzF3XzBBTGRGcEZQQ3FjLWxCQ0locVM2dGZJR1kxYmlBQXdsbFhfbFFISS1wSUkxQmp4U2d2Z3JHbXRPMUpnajBydTRmNnQzZmF5eEdzOVFRNUdDNVV0aDJQNERCaXN3ZGo1UUc1ZGkwOFYzcDgxS1ltZllDeTFxNFIxT3FyOUxLMFNrLUhtOFNFV0xMYkM5TlpWMzk?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "ADMA Biologics Stock Plunges As Legal Probes Escalate", "summary": "", "url": "https://news.google.com/rss/articles/CBMieEFVX3lxTE1UQ012M3g1ZFlWaXNMN3R2aHViTS1VeWRWS3lLTTM4S1paa2Rpem1qdThINnJMcWlyMUNMbTdBb1ZLdkdzZFlSYUNWOUEzNDRTX19FTWJDUTJtM0Nkd0s4QmcwZTk4cTREblFTOEthNS1CUDBHckJmdw?oc=5", "source_name": "StocksToTrade", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ASCENIV Pediatric Approval Tests ADMA Biologics Growth Story And Risks", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADMA Biologics Reports First Quarter 2026 Financial Results and Provides Business Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8gFBVV95cUxQSFZoaGowWXVoLWFZMXRiREVnTWxmRVM1WWlvR19vSXZQZ0E5azJUVGtuQzdwS0V4c09xQWVpbHVxSUxfY3ZhSlRfdTFWNW9BSGY4WHdGSk5sQUVxZG14cUNzY2Y0MnNOSzl5ZnlpYTZhT3k2SWx0cmZuamNTandNUzVGemRoZC1EOEM3aDhKMF9vNWZEQjBnanJjWGIzeEx0dHlzbG9vR2ZwcC1uUlg5X2RVRHZIZUl6ZTZoOWQwMGgtWnFaSnhicU5LZ1FvckEwRW5aLUU4cWVKUFF6bVVYZi16V3kwWnFtSE40b3lyRUFpQQ?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADMA Biologics sets May 6 earnings webcast for 4:30 p.m. ET", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxPcXFBYjlUU3NsYXFfMWJKRVNlQ2xPdmxoZk1JUVdEZlBxSW1TcE1pQmVtZmJueHdpRXJuUlVrZkdLX3ktNThqbWNrelhheElpRUltZHFqeF9PN2ZjMW11NW5YY1dWbGc2djIwY2VMWEhpc2tLWWpPVEt1cjhaVWNHZkVoTG1YdkRUSWRoc0VMOW84UWpvaDNyZ19KOUZaRUlCbnpybUF4YXdGalJlS2R4VW5qRWpud2dKTG03OWI1MzU?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Is ADMA Biologics (ADMA) Falling Share Price Creating A Potential Opportunity For Investors", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4gFBVV95cUxNZW1CMkxadkx3QXBQZGJweG1aNHFHV0Z6TjF1VDZ1VHV4b3ZMQXo5SVBqYTdncEdKazU3c0RUVTJIOWVjb1JTWkI3Z3k0OEM4bmJrZkpsLXR3aXBFZm1IUUZrb1NlSVRrZ0dtbWEtTUd2VzVxZ2RmUTlTTVpnYmlmRkFOdXlxSVJXR2xPcnBNcHRLdWlyY0ZacmJHQnFFa29KWFFmUnhpX1BQUXAyNUpYUXZlcF9IOHZqYXJxSVNVOEg5eTdycUVEWmpGeWpMc1BfQXpaLUFoVlVtSDJ2ZlVGd1BR0gHnAUFVX3lxTE5TY1NOTG1MeFB6UmxlcjZlMmJHaVRTWmd0TWI1aW9xbGt6WUV1TFhHNjUwdUhnZS1GNWxOMWJaZ3JaTjZLNDU5a1BLUXZDQnE1RG9vNnVCdTRfSThTbHB0UnNNWXRzbzVZR2hxamFEeXo0eERFMXg1LTJRMW5kdzhzdWRIVU9USVpaVWhVZVVvWGZHVm5CUXZ6M29iWjZ6UHh2V0ZqZnliY2VlYmt4SEllUE5sQ0pfNU9kcVY1TTJQWWtQdm5BeU5GblRWaWlfRmdRbHhtdXhkSHZXUVo1TklIbjB6RXNjYw?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-24T07:00:00+00:00", "published_display": "24 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxNZXlTZHFHZVNxMktqZ0hVNURmdE1hUFpZZnlfdEVhMnVla2EyTWN6b2YwNkVhNllxUy1Bczl2a0ZUNk04Q3oyTEZSajdpMnFDVXJfRTlfLUdHQ05uS3FQZkhNWkJ0MDFENDJvRXR0ZGV1RDlYVmdWem96V29NeTg4YWRZWGNoMzM1emRoSExJbXdwZnJIWHpsYjVnT0FQVHZtUW5iVg?oc=5", "source_name": "Market source", "published_at": "2026-03-30T07:00:00+00:00", "published_display": "30 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "ADMA Biologics Announces $125 Million Accelerated Share", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgJBVV95cUxPZk5mQWhidTB6MHZWYXJybmJCQkE0dlBXeGM5V0plaWxEMnItS3BqR2hyZjdlcXZfODFWMWpMWWk2R3VGZ3RHNFQzbUZpZmxQX0lURllPSVVJdEJzMlA4QldCWTE2SU1UTHZBSXNWbXRQVVl3SFhSQ1BIRklQN2tSV0R5djJNZ0ZhdWZaRmVub2ZaclBVOGxJenFYbklnRHd6WVgtVXptQk94ak1XcEQwUHc0dHh6ZVN5MHJUSUExWGJfWDV1X2NfMHFRamFmMW03dzRPNGI5NWxfZUNMVFplVWtLVWd1dUdsUENIUnNQMFFYdVlnanBweXBwRmxncGRtLTB4aEE0QlhoempRUmRXWjltSl9YZlludlFrZ0EyeElmUS03ZnRWNHc5M1VFblVlYnVhQlRTYUZlTUNMdnB3NG4wdXd5Zw?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-03-02T08:00:00+00:00", "published_display": "02 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADMA Biologics commits $125M into rapid buyback, targets $200M in 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxNVDh6aDRRUWNrY0xya196cVhLWmRNUkYzT0l3Z2Rzcjdsa0pjanYxUUJQc0VqbW1SQjhKeXlmRUlRSWpQNHJtQjlmY05reVpPZnBGdVQtbzNPQVp2ejlZdXJvMElNcHZrY2NUdU0xcFpNd1dzQVNFQTVEMVJURFFDcGI0TGdsWmFBb3Q1YTduamxabks3QVRtUW9wcjgzOGpTWGZFNC04dnRlRmZVOGlySzROa252NzVMUlhEWQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-02T08:00:00+00:00", "published_display": "02 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADMA Biologics to Report Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxNNS1RanFjRVMzalZwNjZya3otR0lVaUs2V0lrTzdTUDJxdVM1MTJ3dXdYRlRydXQyOHBGWGdIdWZBZmdBU2Zhek5RaERYYnExdi1SVU1ILVlPWEVOcGF1bFBhaDlfSjEwVWlaZkp5TWxDZzJ4ZU1QUkJuOV8zQ1dseWFnUTd5OGhEdnZiclN2X1QxQmJQZThGQVYxYjhhOUdnblhuYzh5bFp1MVNneGhxM3FrcWV0YjZNV3g5QnZWd2FLcjBsRUNmU0dpNHc?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-02-18T08:00:00+00:00", "published_display": "18 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADMA Biologics (ADMA): Firm Updates 2025 Revenue Guidance", "summary": "", "url": "https://news.google.com/rss/articles/CBMihAFBVV95cUxNMnMzQ1NUd3dUakpRcTFkc3ZjTmNtUHNGYlI3UG0tbUpVd3hNcGlSRGJQNGtEa2RYNnpoSHV0em1hS1RHZkV0MDV4ZGFtOGNfbHR4b1NnSlRUMGhqVWxQb0o0dVhqVnNUemtyazlHd3hUWG9IeUo5SmlYWlpPVUJMM1pmME8?oc=5", "source_name": "Market source", "published_at": "2025-12-21T08:00:00+00:00", "published_display": "21 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "With EPS Growth And More, Puma Biotechnology (NASDAQ:PBYI) Makes An Interesting Case", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-12-09T08:00:00+00:00", "published_display": "09 Dec 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "ADMA Biologics, Inc. (NASDAQ:ADMA) Looks Just Right With A 25% Price Jump", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-12-02T08:00:00+00:00", "published_display": "02 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "ADMA Deadline Alert: Levi & Korsinsky Reminds ADMA BIOLOGICS, INC. (ADMA) Investors of Securities Class Action Deadline on August 10, 2026", "summary": "Levi & Korsinsky, LLP reminds investors of ADMA Biologics, Inc. (ADMA) about a securities class action lawsuit deadline on August 10, 2026. The lawsuit alleges ADMA used \"channel stuffing\" to falsely inflate ASCENIV revenues, turning a reported 20% growth into an estimated 3% dec", "url": "https://www.globenewswire.com/news-release/2026/06/22/3315388/3080/en/adma-deadline-alert-levi-korsinsky-reminds-adma-biologics-inc-adma-investors-of-securities-class-action-deadline-on-august-10-2026.html", "source_name": "GlobeNewswire", "published_at": "2026-06-22T13:39:20", "published_display": "22 Jun 2026 13:39", "sentiment": "negative", "sentiment_pct": 15, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADMA Alert: ADMA Biologics Investors may have been Misled", "summary": "A securities fraud class action lawsuit has been filed against ADMA Biologics, Inc. (NASDAQ:ADMA) and its executives. This action follows a significant stock drop attributed to allegations of \"channel stuffing\" by Culper Research, leading to a reported 20% revenue growth in 2025 ", "url": "https://www.globenewswire.com/news-release/2026/06/22/3315140/0/en/adma-alert-adma-biologics-investors-may-have-been-misled-about-alleged-channel-stuffing-contact-bfa-law-about-the-pending-securities-fraud-class-action.html", "source_name": "GlobeNewswire", "published_at": "2026-06-22T10:39:20", "published_display": "22 Jun 2026 10:39", "sentiment": "negative", "sentiment_pct": 15, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "INVESTOR DEADLINE ALERT: ADMA Biologics, Inc. (ADMA) Investors With Substantial Losses Have Opportunity to Lead Class Action Lawsuit", "summary": "", "url": "https://news.google.com/rss/articles/CBMi_gFBVV95cUxOSmlKWmdvNE04a3psTk9ocDljTFdqdGlLTWJ6MWhCRExFRjJWbGM0V1F6aGVYY2hrYW9MMG5NcWlBdHpDSm02SDBkc0ZZYXNlQjFDQjNGTm13UlNvNFo1TW1XWmQwLW5pcXJzeHNFUVpqRGR0UHBEZkxGaGZLX2NRRDZxMWVfcFdVVVVkeGxRZjFNcTVHZW5Nb3lzMGdyMUdBeDR5YzJIem9ZbFFad1R1alI5WEtZTkpjdUFQTWNpdEVBVm9ILUt1SEhPZWFaY3Jvb1FyRkFYajQyQ3JhQ0lLdmJFampibnBPYWJoRWtVNkJLLUtqNzZzU2o4cDBRZw?oc=5", "source_name": "NewMediaWire", "published_at": "2026-06-21T21:40:18+00:00", "published_display": "21 Jun 2026 21:40", "sentiment": "negative", "sentiment_pct": 18, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADMA ALERT: Securities Fraud Class Action Launched Against ADMA Biologics, Inc. \u2013 August 10, 2026 Deadline", "summary": "Levi & Korsinsky, LLP has filed a securities class action lawsuit against ADMA Biologics, Inc. on behalf of investors who purchased securities between August 9, 2024, and March 25, 2026. The lawsuit alleges that ADMA Biologics engaged in an undisclosed related party transaction, ", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/adma-alert-securities-fraud-class-action-launched-against-adma-b-1180017", "source_name": "ACCESS Newswire", "published_at": "2026-06-21T22:39:20", "published_display": "21 Jun 2026 22:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Class Action Lawsuit Filed: ADMA Biologics, Inc. (ADMA) \u2013 Join by August 10, 2026 \u2013 Contact Levi & Korsinsky", "summary": "Levi & Korsinsky, LLP has filed a securities class action lawsuit against ADMA Biologics, Inc. on behalf of investors who purchased securities between August 9, 2024, and March 25, 2026. The lawsuit alleges that ADMA Biologics made false statements, concealed a related party tran", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/class-action-lawsuit-filed-adma-biologics-inc.-adma-%E2%80%93-join-by-au-1179926", "source_name": "ACCESS Newswire", "published_at": "2026-06-21T20:10:15", "published_display": "21 Jun 2026 20:10", "sentiment": "negative", "sentiment_pct": 9, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Reminder for ADMA Biologics Securities Class Action", "summary": "The article serves as a reminder for investors who purchased ADMA Biologics securities between August 9, 2024, and March 25, 2026, to apply as lead plaintiff in a class action lawsuit by August 10, 2026. The lawsuit alleges that ADMA Biologics made false statements, including und", "url": "https://intellectia.ai/news/stock/reminder-for-adma-biologics-securities-class-action", "source_name": "Intellectia AI", "published_at": "2026-06-21T13:09:41", "published_display": "21 Jun 2026 13:09", "sentiment": "negative", "sentiment_pct": 27, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADMA Investors Have Opportunity to Lead ADMA Biologics, Inc. Securities Fraud Lawsuit Filed by The Rosen Law Firm", "summary": "The Rosen Law Firm has filed a securities class action lawsuit against ADMA Biologics, Inc., alleging securities fraud for misleading statements about undisclosed related-party transactions, channel stuffing, and inadequate internal controls. Investors who purchased ADMA securiti", "url": "https://www.prnewswire.com/news-releases/adma-investors-have-opportunity-to-lead-adma-biologics-inc-securities-fraud-lawsuit-filed-by-the-rosen-law-firm-302805651.html", "source_name": "PR Newswire", "published_at": "2026-06-21T12:09:40", "published_display": "21 Jun 2026 12:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADMA Biologics (ADMA) Hit With Federal Securities Lawsuit Over Revenue Inflation Allegations", "summary": "ADMA Biologics (NASDAQ:ADMA) is facing a federal securities lawsuit alleging revenue inflation through channel stuffing and concealed distribution relationships, following a short-seller report. This legal challenge comes despite a recent \"Outperform\" rating from Raymond James, w", "url": "https://finance.yahoo.com/markets/stocks/articles/adma-biologics-adma-hit-federal-203437698.html", "source_name": "Market source", "published_at": "2026-06-20T16:34:00", "published_display": "20 Jun 2026 16:34", "sentiment": "negative", "sentiment_pct": 18, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADMA Biologics, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline", "summary": "Kahn Swick & Foti, LLC (KSF) has issued a notice regarding a class action securities lawsuit against ADMA Biologics, Inc. Investors who purchased ADMA securities between August 9, 2024, and March 25, 2026, and suffered losses, have until August 10, 2026, to apply for lead plainti", "url": "https://www.theglobeandmail.com/investing/markets/stocks/ADMA-Q/pressreleases/2560049/adma-biologics-inc-notice-of-august-10-2026-application-deadline-for-class-action-lawsuit-contact-lewis-kahn-esq-at-kahn-swick-foti-llc-before-application-deadline/", "source_name": "The Globe and Mail", "published_at": "2026-06-20T03:40:20", "published_display": "20 Jun 2026 03:40", "sentiment": "negative", "sentiment_pct": 14, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADMA Biologics, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit", "summary": "Kahn Swick & Foti, LLC (KSF) has issued a notice for a class action lawsuit against ADMA Biologics, Inc., informing investors of an August 10, 2026, application deadline to serve as lead plaintiff. The lawsuit alleges that ADMA Biologics and its executives failed to disclose mate", "url": "https://www.streetinsider.com/Newsfile/ADMA+Biologics%2C+Inc.+Notice+of+August+10%2C+2026+Application+Deadline+for+Class+Action+Lawsuit+-+Contact+Lewis+Kahn%2C+Esq.+at+Kahn+Swick+%26+Foti%2C+LLC%2C+Before+Application+Deadline/26668447.html", "source_name": "StreetInsider", "published_at": "2026-06-19T19:38:52", "published_display": "19 Jun 2026 19:38", "sentiment": "negative", "sentiment_pct": 13, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ROSEN, THE FIRST FILING FIRM, Encourages ADMA Biologics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm \u2013 ADMA", "summary": "The Rosen Law Firm is encouraging investors of ADMA Biologics, Inc. (NASDAQ: ADMA) who purchased securities between August 9, 2024, and March 25, 2026, to secure legal counsel before the August 10, 2026 lead plaintiff deadline in a securities class action. The lawsuit alleges tha", "url": "https://www.globenewswire.com/news-release/2026/06/19/3314871/0/en/ROSEN-THE-FIRST-FILING-FIRM-Encourages-ADMA-Biologics-Inc-Investors-to-Secure-Counsel-Before-Important-Deadline-in-Securities-Class-Action-First-Filed-by-the-Firm-ADMA.html", "source_name": "GlobeNewswire", "published_at": "2026-06-19T17:38:52", "published_display": "19 Jun 2026 17:38", "sentiment": "negative", "sentiment_pct": 30, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Adma Biologics Inc (ADMA) Affects Rotational Strategy Timing", "summary": "This article analyzes Adma Biologics Inc (ADMA) using AI models to provide insights for rotational strategy timing. It identifies strong near and mid-term sentiment but a weak long-term outlook, with a notable 159.0:1 risk-reward setup. The report details specific institutional t", "url": "https://news.stocktradersdaily.com/news_release/22/How_Adma_Biologics_Inc_ADMA_Affects_Rotational_Strategy_Timing_061926025601_1781895361.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-19T14:56:00", "published_display": "19 Jun 2026 14:56", "sentiment": "positive", "sentiment_pct": 70, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADMA Shareholder Alert: August 10, 2026 Lead Plaintiff Deadline in ADMA Biologics, Inc. ...", "summary": "The Gross Law Firm has issued a shareholder alert for ADMA Biologics, Inc. (NASDAQ: ADMA) due to alleged materially false and/or misleading statements made during the period of August 7, 2026, to March 25, 2026. Shareholders who purchased ADMA shares during this time are encourag", "url": "https://www.caledonianrecord.com/adma-shareholder-alert-august-10-2026-lead-plaintiff-deadline-in-adma-biologics-inc/article_1366e2c3-815d-523e-a7f2-a3e967a99669.html", "source_name": "Caledonian Record", "published_at": "2026-06-19T14:16:00", "published_display": "19 Jun 2026 14:16", "sentiment": "negative", "sentiment_pct": 13, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADMA INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP", "summary": "Robbins Geller Rudman & Dowd LLP has announced a class action lawsuit against ADMA Biologics, Inc. (NASDAQ: ADMA) for alleged violations of the Securities Exchange Act of 1934. Investors who purchased ADMA securities between August 9, 2024, and March 25, 2026, and suffered substa", "url": "https://www.globenewswire.com/news-release/2026/06/19/3314877/0/en/adma-investor-notice-robbins-geller-rudman-dowd-llp-announces-that-adma-biologics-inc-investors-with-substantial-losses-have-opportunity-to-lead-class-action-lawsuit.html", "source_name": "GlobeNewswire", "published_at": "2026-06-19T14:15:00", "published_display": "19 Jun 2026 14:15", "sentiment": "negative", "sentiment_pct": 19, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADMA Investors Have Opportunity to Lead ADMA Biologics, Inc. Securities Fraud Lawsuit with the Schall Law Firm", "summary": "The Schall Law Firm is reminding investors of a class action lawsuit filed against ADMA Biologics, Inc. for alleged securities fraud. The lawsuit claims that ADMA made false and misleading statements, failed to disclose a related party transaction, used channel stuffing, and lack", "url": "https://www.globenewswire.com/news-release/2026/06/19/3314763/0/en/adma-investors-have-opportunity-to-lead-adma-biologics-inc-securities-fraud-lawsuit-with-the-schall-law-firm.html", "source_name": "GlobeNewswire", "published_at": "2026-06-19T14:10:00", "published_display": "19 Jun 2026 14:10", "sentiment": "negative", "sentiment_pct": 19, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Investor Rights Alert: ADMA Biologics (ADMA) Faces Securities Fraud Class Action after Channel Stuffing Allegations Cause 29% Stock Drop \u2013 Investors Notified to Contact BFA Law", "summary": "A class action lawsuit has been filed against ADMA Biologics, Inc. (NASDAQ:ADMA) and its executives for securities fraud. This action follows a significant stock drop attributed to allegations by Culper Research of channel stuffing to inflate reported revenue growth for 2025. Inv", "url": "https://www.globenewswire.com/news-release/2026/06/19/3314680/0/en/Investor-Rights-Alert-ADMA-Biologics-ADMA-Faces-Securities-Fraud-Class-Action-after-Channel-Stuffing-Allegations-Cause-29-Stock-Drop-Investors-Notified-to-Contact-BFA-Law.html", "source_name": "GlobeNewswire", "published_at": "2026-06-19T10:10:00", "published_display": "19 Jun 2026 10:10", "sentiment": "negative", "sentiment_pct": 10, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "5 Stocks Under $20 That Will Explode", "summary": "The article discusses ADMA Biologics, Inc. (NASDAQ: ADMA) as one of five stocks under $20 with high upside potential, despite facing a federal securities lawsuit alleging channel stuffing and misleading statements. Raymond James issued an \"Outperform\" rating and a $21 price targe", "url": "https://www.insidermonkey.com/blog/5-stocks-under-20-that-will-explode-1784343/5/", "source_name": "Insider Monkey", "published_at": "2026-06-19T00:12:29", "published_display": "19 Jun 2026 00:12", "sentiment": "negative", "sentiment_pct": 39, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Investors Alert: Class Action Lawsuits Against ADMA, ERAS, NNOX", "summary": "Class action lawsuits have been filed against ADMA Biologics, Erasca, Inc., and Nano-X Imaging Ltd. for allegedly making false or misleading statements that led to investor losses. Holzer & Holzer, LLC is representing shareholders in these cases, with deadlines for lead plaintiff", "url": "https://intellectia.ai/news/stock/investors-alert-class-action-lawsuits-against-adma-eras-nnox", "source_name": "Intellectia AI", "published_at": "2026-06-18T21:12:29", "published_display": "18 Jun 2026 21:12", "sentiment": "negative", "sentiment_pct": 17, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADMA Biologics, Inc. (ADMA) Class Action Lawsuit: Investors Face August 10, 2026, Deadline", "summary": "Kessler Topaz Meltzer & Check, LLP has announced a securities fraud class action lawsuit against ADMA Biologics, Inc. (ADMA). The lawsuit alleges material misstatements and omissions regarding the company's revenues and internal controls, including undisclosed related-party trans", "url": "https://www.prnewswire.com/news-releases/adma-biologics-inc-adma-class-action-lawsuit-investors-face-august-10-2026-deadline-302802887.html", "source_name": "PR Newswire", "published_at": "2026-06-18T18:12:29", "published_display": "18 Jun 2026 18:12", "sentiment": "negative", "sentiment_pct": 19, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Deadline Alert: ADMA Biologics, Inc. (ADMA) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAJBVV95cUxPbnZzNklOeGVrd0ludmJLTHpVaVFXcVhaLUh4bWRqTmJDYWlXSnBBVllqWE5NeG1HWEhGNEdPc0ZYN2xkcXc2V2xMWlV3Ym9qLW5lSTVSaklzSWttNndvRmpYa29hLXlyczBZcHZuSjV5ckZsTXJNN2xnQlNaU3g2YXphMkRlWUh1bFgxZDhmUEs5VmExNDV3Q3JfeFY0eTYzX09IU2xqcFotSExPd01EeGV1N0RHSHJITmgxMWN4ODV4ZjdlaVRiRjhNa3dQYlkxZGVTVFp0WGVWakF1aUtsU0FzSGlZVDVHYkgtSGxRNGMwUV9ncGdOejhVOFBpc2JYVmlEN1NlN3ZQcS1GaEd6aWJaaFJPcjhOR0d1LTlSOHlKVVhwUThRWFBMQk9UVFZCdjJUWUxlanJuT3VYT3otVWhvRjQ?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-06-18T16:00:00+00:00", "published_display": "18 Jun 2026 16:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Deadline Alert: ADMA Biologics, Inc. (ADMA) Shareholders", "summary": "Glancy Prongay Wolke & Rotter LLP has issued a deadline alert for investors who lost money in ADMA Biologics, Inc. (ADMA) securities, urging them to contact the firm regarding a securities fraud lawsuit. The class action alleges that ADMA made materially false and misleading stat", "url": "https://www.globenewswire.com/news-release/2026/06/18/3314387/0/en/deadline-alert-adma-biologics-inc-adma-shareholders-who-lost-money-urged-to-contact-glancy-prongay-wolke-rotter-llp-about-securities-fraud-lawsuit.html", "source_name": "GlobeNewswire", "published_at": "2026-06-18T16:12:29", "published_display": "18 Jun 2026 16:12", "sentiment": "negative", "sentiment_pct": 13, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADMA Biologics Shareholder Alert: ClaimsFiler Reminds", "summary": "ClaimsFiler is alerting investors with significant losses in ADMA Biologics, Inc. (NasdaqGM: ADMA) to a lead plaintiff deadline of August 10, 2026, in a securities class action lawsuit. The lawsuit alleges that ADMA and its executives made false and misleading statements, includi", "url": "https://www.globenewswire.com/news-release/2026/06/18/3314344/35454/en/adma-biologics-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-100-000-of-lead-plaintiff-deadline-in-class-action-lawsuit-against-adma-biologics-inc-adma.html", "source_name": "GlobeNewswire", "published_at": "2026-06-18T15:12:29", "published_display": "18 Jun 2026 15:12", "sentiment": "negative", "sentiment_pct": 10, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADMA Shareholder Alert: ADMA BIOLOGICS, INC. Securities Class Action Lawsuit - Investors Should Contact SueWallSt", "summary": "SueWallSt has issued a shareholder alert regarding a securities class action lawsuit against ADMA Biologics, Inc. (NASDAQ: ADMA). The lawsuit alleges the company made misleading statements about its revenue recognition, internal controls, and related party transactions, specifica", "url": "https://www.prnewswire.com/news-releases/adma-shareholder-alert-adma-biologics-inc-securities-class-action-lawsuit---investors-should-contact-suewallst-302803661.html", "source_name": "PR Newswire", "published_at": "2026-06-18T14:12:29", "published_display": "18 Jun 2026 14:12", "sentiment": "negative", "sentiment_pct": 20, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ADMA Biologics, Inc. of Class Action Lawsuit and Upcoming Deadlines - ADMA", "summary": "Pomerantz LLP has filed a class action lawsuit against ADMA Biologics, Inc. (NASDAQ: ADMA) on behalf of investors who incurred losses. The lawsuit alleges securities fraud following a Culper Research report claiming \"channel stuffing\" and an undisclosed related party distributor ", "url": "https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-reminds-investors-with-losses-on-their-investment-in-adma-biologics-inc-of-class-action-lawsuit-and-upcoming-deadlines--adma-302802832.html", "source_name": "PR Newswire", "published_at": "2026-06-18T14:00:28", "published_display": "18 Jun 2026 14:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Grabar Law Office Investigates ADMA Biologics, Inc. (ADMA) on Behalf of Long-Term Shareholders", "summary": "Grabar Law Office is investigating ADMA Biologics, Inc. (ADMA) regarding potential breaches of fiduciary duties by its officers and directors. The investigation focuses on allegations of inadequate internal controls, inflated revenue through channel-stuffing, undisclosed related-", "url": "https://www.newsfilecorp.com/release/302043/Grabar-Law-Office-Investigates-ADMA-Biologics-Inc.-ADMA-on-Behalf-of-LongTerm-Shareholders", "source_name": "TMX Newsfile", "published_at": "2026-06-18T12:40:28", "published_display": "18 Jun 2026 12:40", "sentiment": "negative", "sentiment_pct": 19, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adma Biologics (ADMA) Dips More Than Broader Market: What You Should Know", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxPbk5relpGSkt4ZlNCTkROaHR2aDMzZGliMmVMTlBEbXNtcFZvOUxKWlVYdXN3RU1fVUF4SlFuYTR0Q3RRNmJGQ2xkV0MxT0tYNU1TUnhPWk1GQmdDQjl5a3BrTi1fajJrNjJDcTIyUExfcmdHekV4TGFqcUlSdWotaEhPYnM0WWI4VGo1TnN4eUY0eTFDWTdReVhR?oc=5", "source_name": "Market source", "published_at": "2026-06-17T21:50:02+00:00", "published_display": "17 Jun 2026 21:50", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADMA LAWSUIT ALERT: Bragar Eagel & Squire, P.C. Announces", "summary": "Bragar Eagel & Squire, P.C. announced a class action lawsuit against ADMA Biologics, Inc. (NASDAQ:ADMA) for alleged false and misleading statements, including an undisclosed related party transaction and channel stuffing. The lawsuit covers investors who purchased ADMA securities", "url": "https://www.globenewswire.com/news-release/2026/06/17/3313864/0/en/adma-lawsuit-alert-bragar-eagel-squire-p-c-announces-that-a-class-action-lawsuit-has-been-filed-against-adma-biologics-inc-and-encourages-investors-to-contact-the-firm.html", "source_name": "GlobeNewswire", "published_at": "2026-06-17T22:39:30", "published_display": "17 Jun 2026 22:39", "sentiment": "negative", "sentiment_pct": 13, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Class Action Alert: Levi & Korsinsky Reminds ADMA Biologics, Inc. (ADMA) Investors of August 10, 2026 Deadline", "summary": "Levi & Korsinsky, LLP has filed a securities class action lawsuit against ADMA Biologics, Inc. (NASDAQ:ADMA) on behalf of investors who suffered losses due to alleged securities fraud between August 9, 2024, and March 25, 2026. The lawsuit claims ADMA Biologics engaged in an undi", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/class-action-alert-levi-and-korsinsky-reminds-adma-biologics-inc-1178565", "source_name": "ACCESS Newswire", "published_at": "2026-06-17T21:39:30", "published_display": "17 Jun 2026 21:39", "sentiment": "negative", "sentiment_pct": 19, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADMA DEADLINE: Levi & Korsinsky Reminds ADMA BIOLOGICS, INC. Investors of Upcoming Securities Class Action Deadline", "summary": "Levi & Korsinsky, LLP reminds investors of ADMA Biologics, Inc. (NASDAQ: ADMA) about a looming securities class action deadline of August 10, 2026. The lawsuit alleges that ADMA falsely certified effective internal controls while engaging in a channel stuffing scheme and conceali", "url": "https://www.prnewswire.com/news-releases/adma-deadline-levi--korsinsky-reminds-adma-biologics-inc-investors-of-upcoming-securities-class-action-deadline-302802430.html", "source_name": "PR Newswire", "published_at": "2026-06-17T14:39:30", "published_display": "17 Jun 2026 14:39", "sentiment": "negative", "sentiment_pct": 13, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Portnoy Law Firm Announces Class Action on Behalf of ADMA Biologics, Inc. Investors", "summary": "The Portnoy Law Firm has announced a class action lawsuit against ADMA Biologics, Inc. on behalf of investors who purchased securities between August 9, 2024, and March 25, 2026. The lawsuit alleges that ADMA Biologics and its executives failed to disclose material information, i", "url": "https://www.globenewswire.com/news-release/2026/06/17/3313582/0/en/Portnoy-Law-Firm-Announces-Class-Action-on-Behalf-of-ADMA-Biologics-Inc-Investors.html", "source_name": "GlobeNewswire", "published_at": "2026-06-17T14:06:06", "published_display": "17 Jun 2026 14:06", "sentiment": "negative", "sentiment_pct": 14, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "INVESTOR NOTICE: ADMA Biologics, Inc. (ADMA) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0gJBVV95cUxQV0FqX2QtVE1ESHMzQ0ZRcFVldkV1NjEtejVJbXZwTFR3WkNFdUdudEhtUHQxQ245ZFFVZkU5ME5aUi12bkF1dUlEZUFtN19xQlY4YkFvaGFGdFM3aHBKRE94SHA4WDZ1SUE4OWJVLUlkaV9fUk9OZ3hUaWdnZEgwQWQwN3VIYTY0alczbkNHWFhkRUpVN21rTU42bkVIbVlCMWI3dW8yYWRJa1E1Y2J1TUUwcGxjWDVuVUhSbXE0NGxFSWVqeDUtM0Z6UXZxRWxMYWktaUZtOGNlaHhwdUI0MVZLOXJEMmdvdGFzbU03c19VVk9KVnJuNTJLRm1YR0c3UUs0MEJhb05UQnlFaG1mMUVYblVVcUJkU3F4WHFPbWZvYVhoNmRrSEVDRWZKU3Q4M19lTEE4S0dBT0FLWVdjXzVVdXlkNkxzaWhOeEpYZHVzQQ?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-06-16T21:20:00+00:00", "published_display": "16 Jun 2026 21:20", "sentiment": "negative", "sentiment_pct": 18, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADMA Biologics (ADMA) Stock Valuation After Revenue Inflation Lawsuits And Governance Concerns", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-14T11:25:16+00:00", "published_display": "14 Jun 2026 11:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADMA Biologics Faces Class Action Lawsuit for Securities Fraud", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxNYnl0STRMbFBGZHZRSGlsRzFBdXR4UTVHYjBmSFBFUWtZOTd1R1dRN1Rmc2E1YnZtazQwSlBDaVNHbWpDbzRlWk9xNlAzV3RHcGxCZUFIRnJha0dhelVHSW5jX05ObWtrMXJnZWw4SjJSU3hTdVc0c1FQUGhRS2NTMURpUy1JTG96Z3VEOEFRRS1LQ1NsdDQ2dHJEbmY?oc=5", "source_name": "Intellectia AI", "published_at": "2026-06-12T11:57:07+00:00", "published_display": "12 Jun 2026 11:57", "sentiment": "negative", "sentiment_pct": 34, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adma Biologics (ADMA) Stock Dips While Market Gains: Key Facts", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPMmYzT05rY0sxSzNkSDNoaHBiZDFvZ1hUVE4wVDhiVWNXWVJnWUpNTC16Y2p4cVpZS0JwdzNZdHQtaUFzR1JTdDN4Ri13bDBfT1JQWWVZMk1NTVh3M3poZjNVX0xFNGFFWnZ6M1ZadVEzaXJkY3NPUHRISGFWWFBIREUzdkotUWZzLXpPMFRvMFNzSHQyVnhjQlJxWQ?oc=5", "source_name": "Market source", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why ADMA Biologics (ADMA) Is Up 9.3% After Securities Fraud Class Actions Over ASCENIV Sales Practices", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4gFBVV95cUxQcVZOZlVXNkhhWmVTTzVLa09yQ1g0R2RPdEE1RmN0cHhjZUZzenA3Z0Y2UzhUY21JS180QlZaRlNXd1VkOW50SWJPaVJNVnIxY085b1FWNGR4SUVXbndVM3JpSTFrRjhaZ0hyMG9uTEVMdzFPWnlra01KRlYxa0p2SG03bElIUmdzcjJfQUItRHk1YXJNa2w3NWNUNzRKR3MyLVVWT3cxVVJFWjNLWjVzSWhWZGI0YWM3blA1eTBOOVFvM3RLOFhuZENIYXBwUXlTakNGR1dfbUVubjNydnFhZVFR?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Investor Notice: Robbins LLP Informs Investors of the ADMA Biologics, Inc. Class Action Lawsuit", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5AFBVV95cUxOelZJN0wyeXFUOVBvZkozVnZzVUNxU2dvelotZXBkd2dGNU02X0lSaXBOamZZV1NZVGhHNTIzckxZWm43S1A5SGZTYUdfQnMyei1iWHk0dlVxVXFpeDdMZXBlbDVLbS1BVkR0b094LXdLUGU5TEJwakNuRUZKTHg4WEFqYU5aTGNiMHR0R3dPTVFQdUk4VE0zMjhWUjg4UjRsVFhweXdmejRHeGlnS0hsaFl5R0lkem9kaDQzX1lBOTdaYXczVzFVTWJ6Z3ZzZE5ZN2RveEFOVkdsVjc2b3Q0SllaQXc?oc=5", "source_name": "Business Wire", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adma Biologics (ADMA) Down 5.8% Since Last Earnings Report: Can It Rebound?", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/adma-biologics-adma-down-5-153018267.html", "source_name": "Zacks", "published_at": "2026-06-05T15:30:18+00:00", "published_display": "05 Jun 2026 15:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADMA Biologics (ADMA) Valuation After 2026 Guidance Reset And BIVIGAM Headwinds", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/adma-biologics-adma-valuation-2026-200843695.html", "source_name": "Simply Wall St.", "published_at": "2026-06-01T20:08:43+00:00", "published_display": "01 Jun 2026 20:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADMA Biologics (ADMA) Receives FDA Label Expansion for ASCENIV", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/adma-biologics-adma-receives-fda-113719750.html", "source_name": "Insider Monkey", "published_at": "2026-06-01T11:37:19+00:00", "published_display": "01 Jun 2026 11:37", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is ADMA Biologics, Inc. (ADMA) Among the Best Russell 2000 Stocks to Invest In According to Hedge Funds?", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/adma-biologics-inc-adma-among-080341722.html", "source_name": "Insider Monkey", "published_at": "2026-06-01T08:03:41+00:00", "published_display": "01 Jun 2026 08:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADMA Biologics Inc (ADMA) Stock Analysis: Exploring a 109.90% Potential Upside Amid Robust Revenue Growth", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxQY1VPcVJQZjdPY0Iyc2ZjWUg3TUpMQjZwSGloM1QzYUcxZTFYejVoa1liYjNzMjNtMGZySExFSXRYRFBZdVo1YUNQdFhfaFp2RERsN3dFMWhTb1Z5RVJfd1V4aXItWUM3UjYzdXl0WEs0OWJYZmJDUTRHcHctMnlmclk2VlJnU3NMRG5NVlRiZ25CNGUycEtUYUsyVkRIU3IyZUFlS2p2a3k2bzZRelBwTVNIdmtjX1FFcXJJQlZBeEUxVEh3bWo2QWFEN3lNM3l2OVNYR0hFa0tPRnMyYVJQSE1MZ3VJMlU?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is it Time to Exit ADMA Biologics Stock After a 22% Monthly Plunge?", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxNQS16dklZVlVqakZoSVJ5LXBfQkk4TmI3cGFFTjlHR0hEZnJkbWlUeWNkRXZQRjNmb1RYdTRfMnlDT0p6QUQ5c1JUSGx1ak05dUpnQnRHYUtfcFJuczRrWUpwc0JqSmNWMzlMX0F5S0hvWm9EZFpycG9EMDFKdkthRTJabThWNkt2cnh6blNxM0MzOHA5WHlyZEZCRQ?oc=5", "source_name": "Market source", "published_at": "2026-05-19T07:00:00+00:00", "published_display": "19 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADMA Biologics Stock Plunges As Legal Probes Escalate", "summary": "", "url": "https://news.google.com/rss/articles/CBMieEFVX3lxTE1UQ012M3g1ZFlWaXNMN3R2aHViTS1VeWRWS3lLTTM4S1paa2Rpem1qdThINnJMcWlyMUNMbTdBb1ZLdkdzZFlSYUNWOUEzNDRTX19FTWJDUTJtM0Nkd0s4QmcwZTk4cTREblFTOEthNS1CUDBHckJmdw?oc=5", "source_name": "StocksToTrade", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ASCENIV Pediatric Approval Tests ADMA Biologics Growth Story And Risks", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADMA Biologics Reports First Quarter 2026 Financial Results and Provides Business Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8gFBVV95cUxQSFZoaGowWXVoLWFZMXRiREVnTWxmRVM1WWlvR19vSXZQZ0E5azJUVGtuQzdwS0V4c09xQWVpbHVxSUxfY3ZhSlRfdTFWNW9BSGY4WHdGSk5sQUVxZG14cUNzY2Y0MnNOSzl5ZnlpYTZhT3k2SWx0cmZuamNTandNUzVGemRoZC1EOEM3aDhKMF9vNWZEQjBnanJjWGIzeEx0dHlzbG9vR2ZwcC1uUlg5X2RVRHZIZUl6ZTZoOWQwMGgtWnFaSnhicU5LZ1FvckEwRW5aLUU4cWVKUFF6bVVYZi16V3kwWnFtSE40b3lyRUFpQQ?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADMA Biologics sets May 6 earnings webcast for 4:30 p.m. ET", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxPcXFBYjlUU3NsYXFfMWJKRVNlQ2xPdmxoZk1JUVdEZlBxSW1TcE1pQmVtZmJueHdpRXJuUlVrZkdLX3ktNThqbWNrelhheElpRUltZHFqeF9PN2ZjMW11NW5YY1dWbGc2djIwY2VMWEhpc2tLWWpPVEt1cjhaVWNHZkVoTG1YdkRUSWRoc0VMOW84UWpvaDNyZ19KOUZaRUlCbnpybUF4YXdGalJlS2R4VW5qRWpud2dKTG03OWI1MzU?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is ADMA Biologics (ADMA) Falling Share Price Creating A Potential Opportunity For Investors", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-24T07:00:00+00:00", "published_display": "24 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADMA Biologics Announces $125 Million Accelerated Share", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgJBVV95cUxPZk5mQWhidTB6MHZWYXJybmJCQkE0dlBXeGM5V0plaWxEMnItS3BqR2hyZjdlcXZfODFWMWpMWWk2R3VGZ3RHNFQzbUZpZmxQX0lURllPSVVJdEJzMlA4QldCWTE2SU1UTHZBSXNWbXRQVVl3SFhSQ1BIRklQN2tSV0R5djJNZ0ZhdWZaRmVub2ZaclBVOGxJenFYbklnRHd6WVgtVXptQk94ak1XcEQwUHc0dHh6ZVN5MHJUSUExWGJfWDV1X2NfMHFRamFmMW03dzRPNGI5NWxfZUNMVFplVWtLVWd1dUdsUENIUnNQMFFYdVlnanBweXBwRmxncGRtLTB4aEE0QlhoempRUmRXWjltSl9YZlludlFrZ0EyeElmUS03ZnRWNHc5M1VFblVlYnVhQlRTYUZlTUNMdnB3NG4wdXd5Zw?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-03-02T08:00:00+00:00", "published_display": "02 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADMA Biologics commits $125M into rapid buyback, targets $200M in 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxNVDh6aDRRUWNrY0xya196cVhLWmRNUkYzT0l3Z2Rzcjdsa0pjanYxUUJQc0VqbW1SQjhKeXlmRUlRSWpQNHJtQjlmY05reVpPZnBGdVQtbzNPQVp2ejlZdXJvMElNcHZrY2NUdU0xcFpNd1dzQVNFQTVEMVJURFFDcGI0TGdsWmFBb3Q1YTduamxabks3QVRtUW9wcjgzOGpTWGZFNC04dnRlRmZVOGlySzROa252NzVMUlhEWQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-02T08:00:00+00:00", "published_display": "02 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADMA Biologics to Report Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxNNS1RanFjRVMzalZwNjZya3otR0lVaUs2V0lrTzdTUDJxdVM1MTJ3dXdYRlRydXQyOHBGWGdIdWZBZmdBU2Zhek5RaERYYnExdi1SVU1ILVlPWEVOcGF1bFBhaDlfSjEwVWlaZkp5TWxDZzJ4ZU1QUkJuOV8zQ1dseWFnUTd5OGhEdnZiclN2X1QxQmJQZThGQVYxYjhhOUdnblhuYzh5bFp1MVNneGhxM3FrcWV0YjZNV3g5QnZWd2FLcjBsRUNmU0dpNHc?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-02-18T08:00:00+00:00", "published_display": "18 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADMA Biologics (ADMA): Firm Updates 2025 Revenue Guidance", "summary": "", "url": "https://news.google.com/rss/articles/CBMihAFBVV95cUxNMnMzQ1NUd3dUakpRcTFkc3ZjTmNtUHNGYlI3UG0tbUpVd3hNcGlSRGJQNGtEa2RYNnpoSHV0em1hS1RHZkV0MDV4ZGFtOGNfbHR4b1NnSlRUMGhqVWxQb0o0dVhqVnNUemtyazlHd3hUWG9IeUo5SmlYWlpPVUJMM1pmME8?oc=5", "source_name": "Market source", "published_at": "2025-12-21T08:00:00+00:00", "published_display": "21 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADMA Biologics, Inc. (NASDAQ:ADMA) Looks Just Right With A 25% Price Jump", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-12-02T08:00:00+00:00", "published_display": "02 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxNZXlTZHFHZVNxMktqZ0hVNURmdE1hUFpZZnlfdEVhMnVla2EyTWN6b2YwNkVhNllxUy1Bczl2a0ZUNk04Q3oyTEZSajdpMnFDVXJfRTlfLUdHQ05uS3FQZkhNWkJ0MDFENDJvRXR0ZGV1RDlYVmdWem96V29NeTg4YWRZWGNoMzM1emRoSExJbXdwZnJIWHpsYjVnT0FQVHZtUW5iVg?oc=5", "source_name": "Market source", "published_at": "2026-03-30T07:00:00+00:00", "published_display": "30 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "With EPS Growth And More, Puma Biotechnology (NASDAQ:PBYI) Makes An Interesting Case", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-12-09T08:00:00+00:00", "published_display": "09 Dec 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 103, "total_relevant": 59, "sentiment_summary": {"positive": 5, "negative": 30, "neutral": 24, "score": 32, "total": 59, "label": "Cautious news tone", "tone": "negative"}, "classifier": {"primary_event": "regulatory", "primary_label": "Regulatory and legal", "confidence": 80, "events": [{"event": "regulatory", "label": "Regulatory and legal", "weight": 18.15, "count": 33}, {"event": "earnings", "label": "Earnings", "weight": 6.54, "count": 13}, {"event": "general", "label": "Market update", "weight": 5.5, "count": 10}, {"event": "guidance", "label": "Guidance", "weight": 1.1, "count": 2}, {"event": "capital_return", "label": "Capital return", "weight": 0.55, "count": 1}], "positive_events": 5, "negative_events": 30}, "market_context": {"has_market_context": true, "latest_close": 8.31, "latest_week": "2026-06-19", "one_week_move": 1.2, "four_week_move": 0.8, "twelve_week_move": -10.2, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.940974, "market_dynamics_buy_signal": false, "relative_strength": -54.579864, "fair_value_gap": -34.6, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "undecided", "expectation_probability": 52.6486, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "+1.2% over one week, +0.8% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Bad news being absorbed", "tone": "positive", "classification": "negative_absorbed", "summary": "Cautious headlines are being absorbed by price, which can signal underlying demand.", "confidence": 80, "badges": ["Caution agrees with inactive trend"], "opportunities": [], "risks": ["Negative tone is aligned with an inactive trend backdrop."], "event_label": "Regulatory and legal", "sentiment_word": "cautious"}, "charts": {"sources": [{"label": "GlobeNewswire", "count": 14}, {"label": "Market source", "count": 10}, {"label": "simplywall.st", "count": 7}, {"label": "PR Newswire", "count": 5}, {"label": "ACCESS Newswire", "count": 3}, {"label": "Intellectia AI", "count": 3}, {"label": "Insider Monkey", "count": 3}, {"label": "Stock Titan", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 52}, {"label": "Industry context", "count": 7}, {"label": "Sector context", "count": 0}], "events": [{"label": "Regulatory and legal", "count": 33}, {"label": "Earnings", "count": 13}, {"label": "Market update", "count": 10}, {"label": "Guidance", "count": 2}, {"label": "Capital return", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "32/100", "tone": "negative", "text": "Cautious news tone"}, {"label": "Market reaction", "value": "Bad news being absorbed", "tone": "positive", "text": "Cautious headlines are being absorbed by price, which can signal underlying demand."}, {"label": "Primary event", "value": "Regulatory and legal", "tone": "negative", "text": "80/100 classification confidence."}, {"label": "Company focus", "value": "52", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+1.2% over one week, +0.8% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Negative", "tone": "negative", "text": "ADMA Deadline Alert: Levi & Korsinsky Reminds ADMA BIOLOGICS, INC. (ADMA) Investors of Securities Class Action Deadline on August 10, 2026"}], "updated_at": "2026-06-22T20:18:39.297157+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}